Literature DB >> 26558378

Bone remodeling markers: so easy to measure, so difficult to interpret.

E Seeman1, T V Nguyen2,3,4.   

Abstract

Mesh:

Substances:

Year:  2015        PMID: 26558378     DOI: 10.1007/s00198-015-3374-9

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  18 in total

1.  Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.

Authors:  J E Dunford; K Thompson; F P Coxon; S P Luckman; F M Hahn; C D Poulter; F H Ebetino; M J Rogers
Journal:  J Pharmacol Exp Ther       Date:  2001-02       Impact factor: 4.030

2.  Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy.

Authors:  Chih-Tai Leu; Eva Luegmayr; Leonard P Freedman; Gideon A Rodan; Alfred A Reszka
Journal:  Bone       Date:  2005-09-26       Impact factor: 4.398

Review 3.  Bisphosphonates: from bench to bedside.

Authors:  R Graham G Russell
Journal:  Ann N Y Acad Sci       Date:  2006-04       Impact factor: 5.691

4.  Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys.

Authors:  S Y Smith; R R Recker; M Hannan; R Müller; F Bauss
Journal:  Bone       Date:  2003-01       Impact factor: 4.398

5.  Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo.

Authors:  Anke J Roelofs; Charlotte A Stewart; Shuting Sun; Katarzyna M Błażewska; Boris A Kashemirov; Charles E McKenna; R Graham G Russell; Michael J Rogers; Mark W Lundy; Frank H Ebetino; Fraser P Coxon
Journal:  J Bone Miner Res       Date:  2012-04       Impact factor: 6.741

6.  Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption.

Authors:  R Eastell; S P Robins; T Colwell; A M Assiri; B L Riggs; R G Russell
Journal:  Osteoporos Int       Date:  1993-09       Impact factor: 4.507

7.  Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry.

Authors:  E F Eriksen; P Charles; F Melsen; L Mosekilde; L Risteli; J Risteli
Journal:  J Bone Miner Res       Date:  1993-02       Impact factor: 6.741

8.  Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats.

Authors:  Robyn K Fuchs; Roger J Phipps; David B Burr
Journal:  J Bone Miner Res       Date:  2008-10       Impact factor: 6.741

9.  Differing effects of denosumab and alendronate on cortical and trabecular bone.

Authors:  Roger M Zebaze; Cesar Libanati; Matthew Austin; Ali Ghasem-Zadeh; David A Hanley; Jose R Zanchetta; Thierry Thomas; Stephanie Boutroy; Cesar E Bogado; John P Bilezikian; Ego Seeman
Journal:  Bone       Date:  2013-11-22       Impact factor: 4.398

10.  Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.

Authors:  K E Naylor; R M Jacques; M Paggiosi; F Gossiel; N F A Peel; E V McCloskey; J S Walsh; R Eastell
Journal:  Osteoporos Int       Date:  2015-05-20       Impact factor: 4.507

View more
  7 in total

1.  Bone turnover markers: response to comments by Seeman and Nguyen.

Authors:  K E Naylor; R M Jacques; M Paggiosi; F Gossiel; N F Peel; E V McCloskey; J S Walsh; R Eastell
Journal:  Osteoporos Int       Date:  2015-11-11       Impact factor: 4.507

2.  The effect of two doses of dried plum on bone density and bone biomarkers in osteopenic postmenopausal women: a randomized, controlled trial.

Authors:  S Hooshmand; M Kern; D Metti; P Shamloufard; S C Chai; S A Johnson; M E Payton; B H Arjmandi
Journal:  Osteoporos Int       Date:  2016-02-22       Impact factor: 4.507

Review 3.  Biomarkers Predicting Bone Turnover in the Setting of CKD.

Authors:  Pieter Evenepoel; Etienne Cavalier; Patrick C D'Haese
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

4.  Elevated Levels of Peripheral Kynurenine Decrease Bone Strength in Rats with Chronic Kidney Disease.

Authors:  Bartlomiej Kalaska; Krystyna Pawlak; Tomasz Domaniewski; Ewa Oksztulska-Kolanek; Beata Znorko; Alicja Roszczenko; Joanna Rogalska; Malgorzata M Brzoska; Pawel Lipowicz; Michal Doroszko; Anna Pryczynicz; Dariusz Pawlak
Journal:  Front Physiol       Date:  2017-10-31       Impact factor: 4.566

5.  Bone Turnover Status: Classification Model and Clinical Implications.

Authors:  Alexander Fisher; Leon Fisher; Wichat Srikusalanukul; Paul N Smith
Journal:  Int J Med Sci       Date:  2018-02-01       Impact factor: 3.738

Review 6.  Advances and Unmet Needs in the Therapeutics of Bone Fragility.

Authors:  Sabashini K Ramchand; Ego Seeman
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-06       Impact factor: 5.555

7.  Lower serum P1NP/βCTX ratio and hypoalbuminemia are independently associated with osteoporotic nonvertebral fractures in older adults.

Authors:  Alexander Fisher; Wichat Srikusalanukul; Leon Fisher; Paul N Smith
Journal:  Clin Interv Aging       Date:  2017-07-19       Impact factor: 4.458

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.